Ulotaront HCl Crystallization for Impurity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for manufacturing ulotaront hydrochloride (Ulotaront HCl) lack consistency and purity, necessitating improvements to ensure safety and efficacy in pharmaceutical formulations.
Innovation Solution
A solid drug formulation comprising ulotaront HCl particles with specific particle size distribution (D50 of 37 to 98 μm) and controlled impurity levels (Compounds 2, 3, 4, 5) is developed, along with a method to produce hemihydrate R-mandelate salts through crystallization, ensuring purity and consistency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing manufacturing methods are used for ulotaront hydrochloride, then the production process is simpler, but the purity and consistency of the product deteriorates
Solution Approach 1:
The manufacturing process is divided into distinct operational stages: (1) providing ulotaront hydrochloride with specific impurity levels, (2) chromatographically separating impurities from the product, (3) determining impurity amounts through analysis, and (4) processing into finished dosage forms only when quality thresholds are met. This segmentation enables precise control over product purity while maintaining process manageability.
Solution Approach 2:
The method incorporates a feedback mechanism where chromatographic analysis of impurity levels determines whether the ulotaront hydrochloride batch qualifies for processing into finished dosage forms. The impurity determination step provides feedback that gates the subsequent processing step, ensuring only batches meeting quality specifications proceed, thereby guaranteeing product consistency and purity.
2Reliability
If stricter impurity control is implemented, then product safety and purity improve, but manufacturing time and complexity increase
Solution Approach 1:
The method performs preliminary chromatographic separation and determination of impurities before the final processing step. By conducting the impurity analysis and separation operations in advance, the process ensures that only ulotaront hydrochloride batches meeting safety thresholds proceed to dosage form manufacturing, guaranteeing product reliability while optimizing the overall timeline through planned sequencing of operations.
3Manufacturing precision
If chromatographic separation is performed to remove impurities, then product purity increases, but process complexity and cost increase
Solution Approach 1:
Chromatography serves as an intermediary technique between the raw ulotaront hydrochloride material and the final finished dosage forms. This intermediate separation process selectively removes impurities (Compounds 2-5) from the main product, enabling high purity output without requiring complex multi-step purification sequences. The chromatographic step acts as a controlled gateway that simplifies the overall process architecture while achieving the desired purity level.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves enhanced purity and consistency in ulotaront HCl dosage forms, reducing impurity levels and improving manufacturing efficiency.
Implementation Method 1
crystallizing a R-mandelate salt of Compound 3 from a solution comprising acetone or acetonitrile and ≥0.7% water
Data Source
AI summary
This disclosure provides improved methods of manufacturing ulotaront HCl, for reducing impurities in ulotaront HCl, and for processing ulotaront HCl into finished dosage forms.